Table 1 Demographic info and baseline characteristics at initial clinical visit with OMS or PR at SCH (n = 22)
Study Variable | Median (IQR) or number (frequency) |
|---|---|
Female, n (%) | 8 (36) |
Age (yr) | 11 (7–12) |
HLA-B27 positivity, n (%) (15 available) | 1 (7) |
ANA positivity, n (%) (10 available) | 3 (30) |
ESR (mm/hr) at initial visit, (n = 20) | 16 (9–35) |
CRP (mg/dL) at initial visit, (n = 20) | 2.3 (0.8–1.9) |
Treating Service, n (%) | |
Rheum and OMS | 15 (68) |
OMS only | 3 (14) |
Rheum only | 4 (18) |
Multifocal lesions, n (%) | 4 (18) |
Clavicle | 1 (5) |
Lower extremity (femur, tibia/ fibula, foot) | 3 (14) |
Upper extremity (radius/ ulna, humerus) | 1 (5) |
Pre-SCH care, n (%) | |
Outside OMS | 7 (32) |
Biopsies | 9 (41) |
Resection | 1 (5) |
Antibiotics | 16 (73) |
SCH surgical care, n (%) | |
Biopsies (intraoral) | 12 (55) |
Biopsies (extraoral) | 1 (5) |
Return to OR/ additional surgery* | 2 (9) |
SCH medical care, n (%) | |
Antibiotics | 9 (41) |
NSAIDs | 18 (82) |
Glucocorticoids | 10 (45) |
DMARDs (MTX, sulfasalazine) | 9 (41) |
Pamidronate | 6 (27) |
Anti-TNF therapy | 5 (23) |